Back

Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Improving outcomes in heart failure: bench to bedside Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Felix Hofer

Medical University of Vienna, Vienna (Austria)

8 More presentations in this session

Presentation thumbnail
Are heart failure patients with mildly reduced ejection fraction treated according to current international guidelines?
Doctor T. Schupp (Mannheim, DE)
Abstract Slides Video
Presentation thumbnail
The power of optimal medical therapy in heart failure with secondary mitral regurgitation
Unknown A. Borrellas Martin (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Successful treatment of pulmonary hypertension and right heart failure by antibody-based functional blocking of the extra-domain A of fibronectin in a preclinical animal model
Professor M. Franz (Rotenburg an der Fulda, DE)
Abstract Slides Video
Presentation thumbnail
Effects of colchicine treatment after myocardial infarction on top of standard therapy: evidence from a preclinical study
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?
Doctor P. Kolkhof (Wuppertal, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Improving outcomes in heart failure: bench to bedside

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources